Malpractice
Where a warning letter travels next
The last page of a Center for Devices warning letter is not only a request for a fifteen-day reply. It is also a notice that the letter does not stay at FDA.
Other federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.
That paragraph appears, with the same work to do, in the 2026 letters to ZOLL, Abbott Diabetes Care, 3B Medical, and BlephEx, and in the 2025 letter to Technological Medical Advancements. It is not a malpractice verdict. It is not an insurance denial. It is FDA telling the firm that GSA, VA, DoD, and foreign regulators who ask for a CFG may read the same page the public can read.
Insurers and boards are not named in that paragraph. If they use the letter, they do it under their own rules, and that use is not in the FDA file unless they put it in their own public order. The honest remainder: a warning letter can follow a firm into contracting and export paper. It does not, by being posted, become a finding about a clinic’s day-to-day practice.
These notes paraphrase and quote one public FDA warning letter. They are not legal advice. A warning letter is an administrative notice, not a court judgment. Redaction marks such as (b)(4) are FDA’s.